TEST:

LymphoTrack® TRB Assay Panel

In this cohort of PTCL patients receiving consolidative ASCT in CR1, all 4 patients with negative TCR MRD post-ASCT remain in remission at median follow-up of 32.5 months. The negative predictive value of TCR NGS MRD post-ASCT warrants further evaluation.

In this cohort of patients with PTCL receiving consolidative ASCT in CR1, all 4 pts with negative TCR MRD post-ASCT remain in remission at median follow up of 32.5 mo post-ASCT. The negative predictive value of TCR NGS MRD post-ASCT should be further evaluated. Clinical trial information: NCT03297697.

"Overall, NGS-based assessment of TCR clonality in MDS patients resulted in fewer patients interpreted as having clonal T-cell expansions compared to gel-based detection. Samples displaying TCR-clonality as detected by NGS-based methods correlated with elevated proportion of CD3+/CD57+ T-cells. Follow up studies include increase of the dataset size and correlation of clonal T-cell expansions with clinical features and response to therapy."

Subjects initiated treatment with CHOEP (n=16), BV-CHP (n=11), CHOP (n=5), CEOP (n=1) CHOP+azacitidine (n=6), CHOEP+lenalidomide (n=1), EPOCH (n=1). Measurement of peripheral blood TCR at the end of treatment is feasible in peripheral T-cell lymphomas using next generation sequencing with a known tumor clonotype. Detectable TCR at the end of treatment correlates with lack of CR but the majority of patients in complete remission by PET/CT have a detectable TCR clonotype at end of treatment. Longer follow up is required to determine if consolidative transplant alters TCR dynamics.